Table 3.

HFA Results for C1311 and Paclitaxel.

Tx	Cell Line	C1311 Status*	Log10 IC50	Paclitaxel Status*	Log10 IC50	SQ†	P‡	IP§	P‡	Overall	Overall P‡
C1311 + Paclitaxel	UMUC6	Sensitive	-6.92	Sensitive	-8.99	66.1	.0003	51.2	<.0001	58.7	<.0001
	HTB9	Intermediate	-5.64	Sensitive	-8.93	40.5	.065	74.0	.0024	57.2	.0047
	T24	Intermediate	-5.66	Intermediate	-7.36	76.9	.002	55.7	<.0001	66.3	<.0001
	KK47	Resistant	-4.84	Resistant	>-7	70.9	<.0001	59.4	.0002	65.1	<.0001

^*Relative responsiveness to C1311 or paclitaxel of indicated cell line. Of cell lines adaptable to the hollow fiber assay, four cell types of varying in vitro combinations of sensitivities to both drugs were selected for validation in vivo. We have reported in vitro sensitivities to paclitaxel across the BLA-40 panel before [15].

^†Average percentage of control growth across four replicates at the subcutaneous implantation site.

^‡Two-tailed P value for single-sample t test against the hypothesis that the inhibition was 0%.

^§Average percentage of control growth across four replicates at the intraperitoneal implantation site.